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BACKGROUND: Differentiating patients with primary al-
dosteronism caused by aldosterone-producing adenomas
(APAs) from those with bilateral adrenal hyperplasia
(BAH), which is essential for choice of therapeutic inter-
vention, relies on adrenal venous sampling (AVS)-based
measurements of aldosterone and cortisol. We assessed
the utility of LC-MS/MS–based steroid profiling to
stratify patients with primary aldosteronism.
METHODS: Fifteen adrenal steroids were measured by
LC-MS/MS in peripheral and adrenal venous plasma
from AVS studies for 216 patients with primary aldoste-
ronism at 3 tertiary referral centers. Ninety patients were
diagnosed with BAH and 126 with APAs on the basis of
immunoassay-derived adrenal venous aldosterone later-
alization ratios.
RESULTS: Among 119 patients confirmed to have APAs
at follow-up, LC-MS/MS–derived lateralization ratios of
aldosterone normalized to cortisol, dehydroepiandros-
terone, and androstenedione were all higher (P 
0.0001) than immunoassay-derived ratios. The hybrid
steroids, 18-oxocortisol and 18-hydroxycortisol, also
showed lateralized secretion in 76% and 35% of patients
with APAs. Adrenal venous concentrations of glucocor-
ticoids and androgens were bilaterally higher in patients
with BAH than in those with APAs. Consequently, pe-
ripheral plasma concentrations of 18-oxocortisol were
8.5-fold higher, whereas concentrations of cortisol, cor-
ticosterone, and dehydroepiandrosterone were lower in
patients with APAs than in those with BAH. Correct
classification of 80% of cases of APAs vs BAH was
thereby possible by use of a combination of steroids in
peripheral plasma.
CONCLUSIONS: LC-MS/MS–based steroid profiling dur-
ing AVS achieves higher aldosterone lateralization ratios
in patients with APAs than immunoassay. LC-MS/MS
also enables multiple measures for discriminating unilat-
eral from bilateral aldosterone excess, with potential use
of peripheral plasma for subtype classification.
© 2015 American Association for Clinical Chemistry
Primary aldosteronism is the most frequent cause of sec-
ondary hypertension and is responsible for 5%–15% of
cases of increased blood pressure among hypertensive
populations (1 ). Increased blood pressure results from
excess adrenal production of aldosterone, also adversely
impacting the cardiovascular system, resulting in in-
creased mortality independent of and additive to related
increases in blood pressure (2–5 ). The cardiovascular
risks of primary aldosteronism can be substantially miti-
gated by appropriate therapy, but this must be tailored
according to the specific nature of the disease (5–7 ).
The two main forms of primary aldosteronism are
(a) unilateral excessive adrenal aldosterone secretion
usually caused by an aldosterone-producing adenoma
(APA)10 and best treated by adrenalectomy, and (b) bi-
lateral excessive aldosterone secretion, commonly as-
cribed to bilateral adrenal hyperplasia (BAH) and most
appropriately treated with mineralocorticoid receptor an-
tagonists. Distinguishing the 2 subtypes depends largely on
adrenal venous sampling (AVS) studies to determine unilat-
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eral vs bilateral adrenal sources of excess aldosterone (8).
Standard AVS procedures depend on comparisons of
plasma aldosterone in each adrenal vein, normalized to con-
centrations of cortisol, to establish presence or absence of
asymmetric aldosterone production (9).
Apart from the difficulty, complexity, and expense
of AVS (10 ), there are several other limitations to the
procedure. Concomitant autonomous adrenal cortisol
overproduction can obscure the presence of unilateral
aldosterone excess (11, 12 ). Because cortisol has a long
plasma half-life, relative differences in peripheral to adre-
nal venous concentrations do not always accurately indi-
cate selectivity of AVS (13 ). There are also well-known
inaccuracies in immunoassay methods (14–22) that may
particularly impact adrenal venous measurements of ad-
renal steroids, such as aldosterone, where immuno-cross-
reactivity with high concentrations of other steroids
could compromise results.
Recognizing the above shortcomings, we established
steroid profiling with LC-MS/MS for subtyping patients
with primary aldosteronism (23 ). The hybrid steroids
18-oxocortisol and 18-hydroxycortisol may be useful for
such subtyping (24–27) and were included in the panel.
In the study reported here, we took advantage of samples
collected during AVS studies at 3 tertiary referral centers
where patients with BAH and APAs were distinguished
on the basis of immunoassay measurements of aldoste-
rone and cortisol. Because those immunoassay measure-
ments provided the reference standard for subtyping, it
was not possible in this retrospective series to establish
whether LC-MS/MS provided superior discriminatory
diagnostic power over immunoassay measurements. In-
stead, the study had 3 objectives: (a) to establish the
impact of any differences between LC-MS/MS and im-
munoassay measurements on aldosterone lateralization ra-
tio; (b) to investigate the utility of alternative steroids to
cortisol as normalizers for estimation of aldosterone lateral-
ization ratios; and (c) to characterize the presence of differ-
ences in adrenal steroid production among patients with
APAs and BAH that may translate to differences in periph-
eral plasma concentrations useful for subtype classification.
Materials and Methods
PATIENTS
Patients were included in the study when the diagnosis of
primary aldosteronism was confirmed by an intravenous
saline infusion or a fludrocortisone-suppression test. In-
clusion also required demonstration of bilateral selectiv-
ity of AVS, confirmed according to ratios of metaneph-
rine or adrenal steroids in adrenal to peripheral venous
plasma (13, 23 ). Follow-up of patients with APAs was
also required to verify the diagnosis.
On the basis of the above criteria, the study included
216 patients with primary aldosteronism who underwent
AVS sampling procedures at 3 tertiary referral centers
(Table 1). Study protocols were approved by institutional
ethics committees at all centers. At Nijmegen, the ethics
committee waived requirements for informed consent for
the first 7 patients. All other patients provided written
informed consent.






Gender, M/F 81/45 68/22 0.1005
Age, years 52 (44–60) 50 (43–59) 0.5119
Systolic BP, mmHg 152 (140–190) 153 (137–166) 0.5069
Diastolic BP, mmHg 93 (85–102) 93 (85–100) 0.9753
Daily defined dose 3.0 (2–4.3) 2.3 (1–3.8) 0.0267
Potassium, mmol/L 3.3 (3.0–3.6) 3.5 (3.3–3.9) <0.0001
Aldosterone, ng/L 235 (168–392) 179 (128–239) <0.0001
Renin, mU/L 3.6 (2.2–8.8) 4.7 (3.0–11.7) 0.0346
ARRb 61 (26–116) 32 (16–53) <0.0001
a Data for continuous variables are median (interquartile range).
b Calculated using ng/L concentrations of aldosterone to mU/L concentrations of renin. To convert aldosterone from ng/L to nmol/L, divide by 360.44. To convert renin from mU/L to
ng/L, multiply by 0.39.
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ADRENAL VEIN SAMPLING
All AVS studies were carried out after adjustment of an-
tihypertensive medication according to accepted recom-
mendations (8 ). Patients received potassium supplemen-
tation to correct hypokalemia. Sequential catheterization
of the adrenal veins was performed at all centers. Contin-
uous cosyntropin stimulation (50 g/h) was used during
AVS procedures at Nijmegen, whereas procedures at the
2 other centers were performed without cosyntropin.
We collected blood samples (2–8 mL) from both
adrenal veins by gravity or gentle negative pressure, with
additional collections (8 mL) of peripheral venous blood
for assessing selectivity of AVS and contralateral suppres-
sion of aldosterone secretion as described (10, 13, 23 ).
Samples were collected into tubes containing lithium
heparin (Nijmegen and Düsseldorf) or EDTA (Munich)
as anticoagulants, transported on ice to laboratories
within 15 min of collection, and centrifuged at 3000–
3500g (4 °C) for 10–15 min. We used a portion of the
plasma immediately for routine immunoassay measure-
ments of cortisol and aldosterone and stored another por-
tion at 70 °C or less until it was sent on dry ice to
Dresden for LC-MS/MS steroid profiling.
SUBTYPE DIAGNOSES
Subtyping patients to either BAH or APA groups was
based on calculations of the lateralization ratio, according
to immunoassay measurements of plasma aldosterone
(A) and cortisol (C) concentrations in both adrenal veins
and defined as the ratio of the higher (dominant) over the





Plasma aldosterone was measured at Munich and
Düsseldorf with a commercial RIA (Coat-a-count, Sie-
mens Healthcare), whereas aldosterone was measured at
Nijmegen with an in-house RIA. Cortisol was measured
with an automated chemiluminescence assay (Liaison,
Diasorin) at Munich, whereas electrochemiluminescence
immunoassays at Nijmegen and Düsseldorf used the
Modular E170 and Elecsys (Roche Diagnostics) analyz-
ers, respectively. Performance characteristics of these as-
says are detailed elsewhere (13, 23, 28 ).
Patients subtyped to the APA group, on the basis of
immunoassay-based lateralization ratios 4.0, all under-
went laparoscopic adrenalectomy, whereas those diag-
nosed with BAH according to a lateralization ratio of
4.0 were treated with mineralocorticoid receptor an-
tagonists (Fig. 1A). There were 5 exceptions involving
patients with lateralization ratios 4.0 (3.8, 3.5, 3.4, 3.1,
and 2.1) who underwent adrenalectomy. In these cases,
the decision to operate was reached by consensus, on the
basis of clinical details and computed tomographic scans
indicating a high likelihood of APA: young age, hypoka-
lemia, suppressed renin, and unilateral adrenal mass.
Consequently, 90 patients were assigned a diagnosis of
BAH and 126 a diagnosis of APA. These designations are
an oversimplification, since it must be recognized that in
some patients the diagnosis of BAH may reflect bilateral
APAs, whereas in others there may be unilateral or asym-
metric hyperplasia and classification by AVS as an APA.
Furthermore, lateralization ratio cutoffs of 4.0 are some-
what arbitrary and may not always accurately distinguish
BAH from APA. For these reasons, follow-up is manda-
tory for all patients operated for an APA.
FOLLOW-UP
Among the patients subtyped with APAs, postoperative
information was available at 6–12 months after surgery
in all except 1 patient whose follow-up was at 3 months.
Outcomes of surgery were categorized as cure, improve-
ment, or failure. We defined cure as office systolic and
diastolic blood pressure 140 and 90 mmHg, no use
of antihypertensive medications, serum potassium 3.5
mmol/L, and a normalized aldosterone-to-renin ratio
(ARR). We defined failure as a continuing increase of the
ARR followed by a positive saline suppression test. In 1 of
Fig. 1. Decision and outcome classification tree for AVS im-
munoassay– based subtyping and therapy of patients with
primary aldosteronism (A) in relation to outcome assessed by
patient follow-up (B) and separate classification of subtype and
outcome on the basis of LC-MS/MS– based measurements of 12
adrenal steroids in peripheral venous plasma (C).
Five patients with immunoassay-derived lateralization ratios (LR)
<4.0 were nevertheless assigned to the group for adrenalectomy
(ADX) rather than the group receiving mineralocorticoid receptor
antagonist (MRA) therapy.
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14 patients with APAs in whom a follow-up saline infu-
sion test was not possible, failure was based on a remain-
ing increase of the ARR, low serum potassium, lack of
decrease in blood pressure, and no change in antihyper-
tensive medication use on follow-up. All other patients
followed up postoperatively were defined as improved.
LC-MS/MS–BASED STEROID PROFILING
We measured 15 adrenal steroids simultaneously by LC-
MS/MS, including aldosterone, cortisol, 18-oxocortisol,
18-hydroxycortisol, cortisone, 11-deoxycortisol, 21-
deoxycortisol, corticosterone, 11-deoxycorticosterone,
progesterone, 17-hydroxyprogesterone, pregnenolone,
androstenedione, dehydroepiandrosterone (DHEA), and
DHEA-sulfate (DHEA-S). Full details of the method,
including validation and assay performance characteris-
tics, are described elsewhere (23 ).
STATISTICAL ANALYSES
For comparisons to APA groups, we defined dominance
of adrenal venous lateralization in patients with BAH by
a lateralization ratio 1.0 as measured by LC-MS/MS.
Statistical analyses used the JMP statistics software pack-
age (SAS Institute). Data are expressed as medians and
interquartile ranges. We used Mann–Whitney U and
Wilcoxon matched paired sign-rank tests to assess signif-
icance of differences involving 2 groups (i.e., BAH vs
APA) or paired comparisons (i.e., dominant adrenal vein
vs nondominant adrenal vein). We used Kruskal–Wallis
and Steel–Dwass all-pairs methods for nonparametric
comparisons involving 3 groups (e.g., APA success vs
failure vs BAH). Relationships were assessed by 1-tailed
Spearman correlation coefficient (rs). We used discrimi-
nant analysis to assess how combinations of steroids
could be used to correctly classify tumors into BAH and
APA groups as well as to subclassify patients with APAs
according to cure, improvement, and treatment failure.
Least squares multivariate analyses were used to assess
relationships of different variables (e.g., cosyntropin vs
no cosyntropin and BAH vs APA) to steroid profiles.
Data were logarithmically transformed before parametric
statistical tests.
Results
PATIENT CHARACTERISTICS AND OUTCOMES
Compared with the 126 patients subtyped with APA, the
90 patients with BAH had baseline characteristics at
study entry indicating overall less severe disease (Table 1).
Among the 126 patients with APAs, 32 (25%) showed
complete cure after adrenalectomy, 87 (69%) showed
improvement that included no remaining biochemical
evidence of primary aldosteronism, and 7 patients (6%)
showed remaining biochemical evidence of primary aldo-
steronism on follow-up (Fig. 1B). All 7 patients in the
treatment-failure group also showed lack of postoperative
decreases in blood pressure and no decrease in antihyper-
tensive medications at follow-up (see Supplemental Ta-
ble 1, which accompanies the online version of this article
at http://www.clinchem.org/content/vol62/issue3). Po-
tassium was also lower postoperatively in these patients
than in the 119 patients with APAs who showed im-
provement or cure and were categorized together in a
single treatment success group.
IMMUNOASSAY- VS LC-MS/MS–DERIVED LATERALIZATION
RATIOS
Strong positive relationships (P  0.0001) were observed
between measurements of cortisol (rs  0.976, P 
0.0001) and aldosterone (rs  0.932, P  0.0001) by
immunoassay and LC-MS/MS, but overall both plasma
cortisol and aldosterone were higher (P  0.0001) by
immunoassays than by LC-MS/MS, with the extent of
these differences varying according to center, concentra-
tion range, and sampling site (see online Supplemental
Results and Supplemental Fig. 1).
As a consequence of the differences between immu-
noassay and LC-MS/MS–based measurements, Bland–
Altman plots indicated mean lateralization ratios for al-
dosterone normalized to cortisol that were 38% higher
(P  0.0001) by LC-MS/MS than by immunoassay (Fig.
2A). Lateralization ratios for LC-MS/MS measurements
of aldosterone normalized to androstenedione and
DHEA were 46% higher (P  0.0001) than ratios
derived from immunoassay measurements of aldosterone
and cortisol (Fig. 2B,C). These differences remained sig-
nificant (P  0.005) for each center and, as shown by
Bland–Altman plots, were larger at higher lateralization
ratios. Thus, the largest differences were observed for the
119 patients with APAs, among whom lateralization ra-
tios were 71%–101% higher by LC-MS/MS than by
immunoassay (see online Supplemental Table 2).
Lateralization ratios of immunoassay-measured al-
dosterone normalized for cortisol showed strong positive
(P  0.0001) relationships with ratios of LC-MS/MS–
measured aldosterone normalized for cortisol, andro-
stenedione, and DHEA (see online Supplemental Results
and Supplemental Fig. 2). Nevertheless, 10% of patients
showed LC-MS/MS–derived lateralization ratios that
differed from immunoassay-derived ratios according to
the cutoff of 4.0; these included 17 patients (8%) in
whom LC-MS/MS–derived ratios fell above and
immunoassay-derived ratios fell below 4.0 and 4 patients
(2%) consistently showing the opposite. The first group
included 2 patients who were nevertheless operated for
APAs, both showing LC-MS/MS–derived ratios consis-
tently 50 and favorable responses to adrenalectomy.
There were also 3 patients diagnosed with BAH on the
basis of immunoassay-derived ratios who consistently
showed lateralization ratios by LC-MS/MS of 12.
Steroid Profiling in Primary Aldosteronism
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LATERALIZATION RATIOS OF 18-OXOCORTISOL AND
18-HYDROXYCORTISOL
Lateralization ratios of 18-oxocortisol and 18-
hydroxycortisol—normalized to cortisol, DHEA, or
androstenedione—all were higher (P  0.001) among
the patients with APAs who showed a successful response
to treatment compared to patients designated with BAH
(see online Supplemental Table 2). The differences, how-
ever, were considerably more substantial for 18-
oxocortisol than for 18-hydroxycortisol. By all methods
of normalization, considerably lower (P  0.05) lateral-
ization ratios were estimated for both aldosterone and
18-oxocortisol for the 7 patients designated with APAs
who failed to show a therapeutic response, compared
with the 119 patients with APAs who showed a successful
response to adrenalectomy.
Lateralization ratios for 18-oxocortisol and 18-
hydroxycortisol showed positive (P  0.001) relation-
ships with those of aldosterone for measurements of the
latter by both LC-MS/MS (Fig. 3, A and C) and immu-
noassay (Fig. 3, B and D). Among the APA group, 90
(76%) and 42 (35%) patients showed respective lateral-
ization ratios of 18-oxocortisol and 18-hydroxycortisol
above the cutoff of 4.0, compared to 6 (7%) and 2 (2%)
patients in the BAH group. However, 3 of the 6 patients
in the BAH group with lateralized production of 18-
oxocortisol also showed lateralized production of aldoste-
rone by LC-MS/MS, but not by immunoassay-derived
lateralization ratios 4.0 (Fig. 3, A and B). Three other
patients in the BAH group had strong lateralization of
18-oxocortisol (ratios of 6.7, 9.8, and 12.3) and LC-MS/
MS–derived lateralization ratios for aldosterone between
2.7 and 3.2 (Fig. 3A), among whom 1 patient also had
lateralized 18-hydroxycortisol production (ratio 6.6).
The 2 patients with APAs who had immunoassay-derived
lateralization ratios for aldosterone 4.0 but LC-MS/
MS–derived lateralization ratios 40.0 (see online Sup-
plemental Fig. 2) also had lateralization ratios for 18-
oxocortisol of 52.3 and 119.3 (Fig. 3B) and for 18-
hydroxycortisol of 5.9 and 25.4 (Fig. 3D).
ADRENAL VENOUS STEROID PROFILES
In contrast to the higher (P  0.01) concentrations of
aldosterone, 18-oxocortisol, and 18-hydroxycortisol in
the dominant adrenal veins of patients with APAs than
those with BAH, concentrations of these steroids in non-
dominant adrenal veins were higher (P  0.05) in pa-
tients with BAH than those with APAs (Table 2). Con-
centrations of all 12 other steroids were also higher (P 
0.05) in the nondominant adrenal veins of patients with
BAH than those with APAs. Furthermore, concentra-
tions of cortisol, pregnenolone, 17-hydroxyprogesterone,
21-deoxycortisol, cortisone, androstenedione, DHEA,
and DHEA-S were also higher (P  0.05) in the domi-
nant adrenal veins of patients with BAH compared to
Fig. 2. Bland–Altman plot comparisons of immunoassay-
derived lateralization ratios for aldosterone normalized to
cortisol vs LC-MS/MS– derived lateralization ratios for aldo-
sterone normalized to cortisol (A), androstenedione (B), and
DHEA (C).
Bland–Altman plots are shown as means of lateralization ratios
determined by LC-MS/MS and immunoassay measurements of
aldosterone, on the x axes, vs differences in LC-MS/MS and
immunoassay-derived ratios as a percent of mean values, on the y
axes. The different symbols depict the different centers at which
AVS was carried out, with gray symbols ( , , ) indicating pa-
tients with BAH, and black symbols (Œ, F, ), those with APA.
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those with APAs. These higher concentrations for pa-
tients with BAH compared to APAs remained significant
(P  0.05) for corticosterone, cortisol, progesterone, 21-
deoxycortisol, cortisone, DHEA, and DHEA-S after cor-
rection for any confounding influence of cosyntropin
stimulation.
The differences in adrenal venous concentrations of
steroids between patients with APAs compared to BAH
translated to differences in peripheral venous concentra-
tions for several steroids. Specifically, whereas peripheral
venous concentrations of aldosterone, 18-oxocortisol,
and 18-hydroxycortisol were higher (P  0.05) among
patients with APAs than BAH, peripheral venous con-
centrations of corticosterone, cortisol, DHEA, and
DHEA-S were higher (P  0.05) among patients with
BAH compared with APAs (Table 2).
DISCRIMINATION OF BAH AND APA BY USE OF PERIPHERAL
VENOUS STEROIDS
Although concentrations of 18-oxocortisol in peripheral
venous plasma were 8.5 times higher among patients
with APAs than those with BAH, there was considerable
overlap, so ROC curves indicated poor utility of this
hybrid steroid for distinguishing patients with APAs
Fig. 3. Relationships of lateralization ratios of aldosterone normalized to cortisol (x axes) according to immunoassay (B,D) and
LC-MS/MS (A,C) measurements compared to lateralization ratios of 18-oxocortisol (A, B) and 18-hydroxycortisol (C, D) normalized to
means for cortisol, DHEA, and androstenedione (y axes) in patients with BAH ( ) and APA (treatment success‚; treatment failure ).
Dashed vertical and horizontal gray lines illustrate cutoffs of 4.0 used to determine lateralized secretion. Lines of identity are also shown to
clarify higher or lower lateralization ratios for LC-MS/MS– derived lateralization ratios for 18-oxocortisol and 18-hydroxycortisol and vs LC-MS/
MS– derived (A,C) and immunoassay-derived (B,D) lateralization ratios for aldosterone.
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520 Clinical Chemistry 62:3 (2016)
from those with BAH (Fig. 4, A and B). However, ROC
curve analysis indicated considerably improved diagnos-
tic utility for subtype discrimination when all 15 adrenal
steroids were considered (Fig. 4B). With additional con-
sideration of postadrenalectomy outcome data for sub-
categorizing patients with immunoassay-diagnosed APAs
into groups showing cure or improvement vs treatment
failure, it could be further determined with discriminant
Fig. 4. Dot box and whisker plot of peripheral venous plasma concentrations of 18-oxocortisol in patients with APAs and BAH (A),
ROC curves for distinguishing patients with APAs from BAH by use of peripheral venous 18-oxocortisol vs all 15 adrenal steroids (B),
and results of discriminant analysis by use of peripheral plasma concentrations of steroids for classification according to outcome.
For the latter analysis, 12 adrenal steroids (aldosterone, 18-oxocortisol, 18-hydroxycortisol, 21-deoxycortisol, corticosterone, 11-
deoxycorticosterone, progesterone, 17-hydroxyprogesterone, androstenedione, DHEA, and DHEA-S) were used to classify patients with pri-
mary aldosteronism according to diagnosis of BAH and response to adrenalectomy according to cure, improvement, and treatment failure
among patients subtyped with APAs on the basis of immunoassay-derived lateralization ratios.
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analysis and stepwise variable selection that a selection of
12 adrenal steroids correctly classified 82% (97/119) and
100% (7/7) of patients into those 2 respective groups
(Figs. 1C and 4C). However, 22 (17%) of the 126 pa-
tients subtyped with APAs according to immunoassay-
derived lateralization ratios were classified as having
BAH, and another 22 (24%) of the 90 patients subtyped
with BAH were classified with APAs (Fig. 1C). With
reclassification of cases of treatment failure to the BAH
group, use of peripheral plasma steroids correctly classi-
fied 80% (172/216) of patients to APA and BAH groups.
Discussion
This study illustrates advantages of LC-MS/MS measure-
ments over conventional immunoassay measurements of
aldosterone and cortisol for AVS-based subtyping of pa-
tients with primary aldosteronism. We also establish al-
ternative steroids to cortisol for correcting adrenal venous
aldosterone for dilutional effects of imperfectly selective
AVS, blood flow differences, or other influences that may
erroneously affect interpretations of lateralized aldoste-
rone production. Furthermore, we have expanded on ex-
isting knowledge concerning the utility of the hybrid
steroids, 18-oxocortisol and 18-hydroxycortisol, as addi-
tional biomarkers for discriminating different subtypes of
primary aldosteronism and provide data illustrating that
differences in patterns of adrenal steroid production
among patients with BAH and APAs translate to differ-
ences in peripheral venous steroid profiles that are poten-
tially useful for subtype classification.
Although LC-MS/MS–based steroid profiling is in-
creasingly showing utility for investigations of adrenal
function and dysfunction (22, 29–33), application of
this technology to patients with hypertension caused by
primary aldosteronism has to date been limited, particu-
larly in the context of AVS. Perhaps the closest study to
ours is that by Nakamura et al. (34 ), who reported mea-
surements of 10 adrenal steroids, including aldosterone,
in adrenal venous plasma of 9 patients with primary al-
dosteronism before and after corticotropin stimulation.
In that study, however, aldosterone was measured with
an LC-MS/MS method separate from those used for the
other steroids. A subsequent study involving LC-MS/
MS–based steroid profiling during AVS did not include
aldosterone or involve patients with primary aldosteron-
ism (35 ). Our study is unique in applying LC-MS/MS
profiling of aldosterone, cortisol, and nearly all other
principal adrenal steroids, in addition to 2 hybrid ste-
roids, to a large population of patients with primary al-
dosteronism undergoing AVS for discriminating APA
from BAH.
We previously established that cortisol is inferior to
metanephrine for determining selectivity of adrenal ve-
nous catheterization (13 ). In a subsequent study, we also
established DHEA and androstenedione as further alter-
natives to cortisol for determining selectivity of AVS
(23 ). We show here that DHEA and androstenedione
also provide useful alternatives to cortisol as normalizers
to assess lateralized aldosterone production.
Our findings that lateralization ratios of aldosterone
were considerably higher when measured by LC-MS/MS
compared to immunoassays appears related to higher
concentrations of aldosterone measured in nondominant
adrenal veins (i.e., contralateral to adrenal veins with
higher aldosterone concentrations) by immunoassays
than by LC-MS/MS. This likely reflects relative inaccu-
racy of immunoassays to measure low concentrations of
aldosterone in the venous outflows of adrenals with sup-
pressed aldosterone production, possibly compounded
by antibody cross-reactivity associated with high concen-
trations of other steroids in these outflows. Others have
similarly reported higher concentrations of aldosterone
measured by immunoassays than by LC-MS/MS
(14, 18–20, 22 ), with differences particularly promi-
nent in the lower concentration range. Our data reiterate
the advantages of LC-MS/MS over immunoassays for
measurements of steroids and extend these advantages to
use of AVS for subtyping patients with primary
aldosteronism.
The utility of hybrid steroids, such as 18-oxocortisol
and 18-hydroxycortisol, for subtyping patients with pri-
mary aldosteronism has been a subject of interest by nu-
merous investigators (24–27, 36–39). Most recently,
Satoh et al. reported on the utility of measuring 18-
oxocortisol in peripheral venous plasma to distinguish
patients with BAH from APAs (27 ). Although we could
not establish similar utility in the present study, we could
confirm 8.5-fold higher peripheral venous plasma con-
centrations of 18-oxocortisol in patients with APAs than
BAH, a finding also consistent with earlier studies
(25, 26, 37 ). We have also established elsewhere that in-
creases in plasma 18-oxocortisol among patients with
APAs are particularly prominent and largely confined to
tumors with somatic KCNJ5 (potassium channel, in-
wardly rectifying subfamily J, member 5) mutations
(39 ). In earlier work, Gordon et al. established that in-
creases of 18-oxocortisol are largely confined to patients
with angiotensin-unresponsive APAs (38 ). Because ade-
nomas with mutations of KCNJ5 have a zona fasciculata–
like phenotype, it is possible that these tumors may
correspond to the angiotensin-unresponsive APAs char-
acterized by Gordon et al. (38 ).
Although 18-oxocortisol appears to have limited
value for subtype differentiation, as we now show, this
can be considerably enhanced with inclusion of addi-
tional steroids. Indeed, our analyses showed that steroid
profiles in peripheral samples could identify 75 of the 97
patients (77%) who did not benefit from adrenalectomy
or who were indicated by AVS to have BAH (Fig. 1C).
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This could thereby potentially avoid the need for AVS in
such patients. However, it must also be recognized that
not all patients with APAs could be distinguished from
those with BAH, so that any use of peripheral steroids
for subtyping and minimizing requirements for AVS
would likely require additional consideration of imag-
ing characteristics.
Although this study outlines promise for LC-MS/
MS–based steroid profiling for subtyping of patients
with primary aldosteronism, there are limitations. One
concerns use of cosyntropin stimulation at 1 of the 3
centers where AVS was performed, which complicates
interpretation of differences in steroid profiles. Neverthe-
less, even with this limitation, findings of differences be-
tween LC-MS/MS and immunoassays that were consis-
tent among centers adds strength to the conclusion that
LC-MS/MS achieves higher aldosterone lateralization ra-
tios in patients with APAs than by immunoassay. The
second, more important, limitation was that LC-MS/MS
measurements were not used for diagnostic decision-
making, which remained based on results of routine im-
munoassays. Thus, for some patients designated with
BAH with immunoassay measurements, lateralization ra-
tios on the basis of LC-MS/MS measurements were
above the usual cutoff of 4.0, and it remains unclear
whether these patients may have benefited from adrenal-
ectomy. As pointed out elsewhere (40 ), such cutoffs are
somewhat arbitrary and potentially misleading. For ex-
ample, therapeutic responses to adrenalectomy among
patients of the present study were highly variable and
included treatment failure in 7 patients, presumably a
consequence of asymmetric bilateral disease. Among
these 7 patients, it is noteworthy that all were correctly
classified by peripheral steroid profiles.
With consideration of the above, clearly there is
need for improved classification not only to distinguish
patients with BAH from those with APAs, but also to
identify which of the latter group will show the most
benefit from surgical intervention. The present study ad-
dresses this need by establishing that compared with
immunoassay-derived measurements, LC-MS/MS achieves
enhanced magnitudes of measured aldosterone lateraliza-
tion ratios in patients with APAs and provides multiple
measures for discriminating APAs from BAH, the latter
with potential application to measurements in peripheral
plasma. With the necessary proof-of-principal data in
hand, it is now possible to proceed to a prospective study
in which LC-MS/MS–based steroid profiling guides di-
agnostic decision-making. From there, it might be possi-
ble for translation to routine clinical practice.
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